Longitudinal data reveal consistent initial responsiveness to targeted agents but limited durability once patients cycle through both BTKi and BCL2i classes.

Micro-Raman spectroscopy, integrated with statistical analysis, discriminates CLL prognostic groups, revealing biochemical heterogeneity beyond conventional molecular markers. The method identifies ...

As therapy for chronic lymphocytic leukemia (CLL) continues to evolve, 2025 brought research, regulatory news, and expert ...

Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized ...

Expert Rev Hematol. 2013;6(4):441-449. The newest biological variables of prognostic relevance are useful for understanding the clinical heterogeneity of disease, however, their value at the time of ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Jim Plotkin shares his personal experience with CLL, including his initial symptoms, the diagnostic process, challenges faced, and advice for patients with newly diagnosed CLL. Medical experts discuss ...

The Haslam 3 Foundation has donated $2 million to Pelotonia, supporting their mission of fighting cancer. The donation, led by Dee and Jimmy Haslam, will specifically support research on Chronic ...

DEAR DR. ROACH: I’m 71 years old. In 2021, lymphocytosis was found during my pre-op workup for breast cancer. I had a successful lumpectomy and radiation, and I am on a five-year course of anastrozole ...